Forj Medical Names Leadership Team for Costa Rica Plant

Why It Matters

The leadership team enables rapid ramp‑up of production capacity, strengthening Forj’s global supply chain and offering customers faster access to high‑precision medtech components. It also underscores Costa Rica’s growing role as a strategic manufacturing hub for the medical device industry.

Key Takeaways

• New 53,000‑sq‑ft plant in Costa Rica ready for production.
• Alfredo González Arce appointed site director, overseeing operations.
• Emilia Garnier leads HR, shaping workforce strategy.
• Ronny Orozco manages facilities, cleanroom and utilities.
• Facility expands Forj’s global manufacturing network across US, Asia.

Pulse Analysis

Costa Rica’s strategic location, favorable trade agreements and a skilled, bilingual workforce make it an attractive destination for medtech manufacturers seeking to diversify production. Forj Medical’s 53,000‑square‑foot advanced manufacturing campus leverages these advantages, positioning the company to meet rising demand for high‑complexity devices while reducing reliance on traditional hubs in the United States and Asia. The plant’s capabilities—ranging from coil winding to precision device assembly—align with industry trends toward localized, flexible supply chains that can quickly adapt to regulatory changes and market fluctuations.

The appointment of seasoned executives underscores Forj’s commitment to operational excellence. Site director Alfredo González Arce brings 18 years of Costa Rican medtech experience, ensuring smooth integration of automated and manual assembly lines. Senior HR business partner Emilia Garnier, with over 25 years in multinational talent management, will craft a workforce strategy that attracts and retains the specialized skills needed for complex device production. Facilities manager Ronny Orozco’s two‑decade engineering background guarantees that cleanroom environments and utility systems meet stringent FDA and ISO standards, a critical factor for client confidence.

Forj’s expansion reflects a broader shift among contract development and manufacturing organizations toward multi‑regional footprints. By adding a Costa Rican node, the company enhances supply chain resilience, shortens lead times for North and South American customers, and offers a cost‑effective alternative to Asian production. This move is likely to encourage other CDMOs to explore Central America, accelerating the region’s emergence as a key player in the global medical device ecosystem.